SLXN — Silexion Therapeutics Corp
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 2022416 ·
Last close
$0.43
Market Cap
$1.80M
52W High
$2.04
52W Low
$0.23
ADV30
11,650,642
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -2,749,000 | -2,733,000 | 4,602,000 | 2,413,000 | 4,311,000 |
| Dec 2025 | 0 | — | -4,406,000 | -4,412,000 | 7,215,000 | 5,991,000 | 4,612,000 |
| Sep 2025 | 0 | — | -3,292,000 | -3,262,000 | 11,614,000 | 9,243,000 | 4,637,000 |
| Jun 2025 | 0 | — | -2,284,000 | -2,503,000 | 5,797,000 | 3,466,000 | 5,677,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-10,819,000
Investing CF
$-14,000
Financing CF
$15,640,000
CapEx
$-25,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-276.71
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-55,166,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-11,890,000
Pretax Income TTM
$-11,909,000
Interest Exp TTM
$19,000
Analysts
2
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -11,632,000 | -11,912,000 | 7,215,000 | 4,612,000 | — | -10,819,000 |
| Dec 2024 | 0 | -12,571,000 | -16,443,000 | 2,863,000 | 6,852,000 | — | -8,396,000 |
| Dec 2023 | 0 | -4,681,000 | -4,942,000 | 5,256,000 | 17,312,000 | — | -4,529,000 |
| Dec 2022 | 0 | -3,860,000 | -3,215,000 | 9,333,000 | 16,412,000 | — | -3,335,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.64
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SCNI | Scinai Immunotherapeutics Ltd. | $1.91M | $0.48 | — |
| ABPO | Abpro Holdings, Inc. | $967.0K | $0.16 | — |
| AIM | AIM ImmunoTech Inc. | $3.39M | $0.23 | — |
| CERO | CERO THERAPEUTICS HOLDINGS, INC. | $947.4K | $0.02 | — |
| CLDI | Calidi Biotherapeutics, Inc. | $3.42M | $0.18 | — |
News headlines (Yahoo Finance, 1h cache)
Silexion Therapeutics Announces 1-for-10 Reverse Share Split
2026-05-26 12:30 · Yahoo
Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-18 12:30 · Yahoo
Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds
2026-05-15 12:27 · Yahoo
Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer
2026-05-14 13:27 · Yahoo
Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center
2026-05-13 12:00 · Yahoo
Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany’s BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer
2026-04-28 12:45 · Yahoo
Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
2026-03-24 13:46 · Yahoo
Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
2026-03-17 21:01 · Yahoo
Silexion Therapeutics Urges Shareholders to Vote Ahead of March 16 Extraordinary General Meeting
2026-03-05 13:00 · Yahoo
Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit
2026-01-21 13:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.